Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired DermTech securities between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”). Investors have until December 14, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company experienced challenges with collections from commercial payors; (2) as a result, there was a lower average selling price for the DermTech Melanoma Test; (3) as a result of the foregoing, the Company's revenue growth would be adversely impacted; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired DermTech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231017323418/en/